• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula

    3/7/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    The strategic arrangement fuels Dario's B2B2C sales growth, expanding access to over 15,000 providers nationwide

    NEW YORK, March 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a strategic collaboration with Rula Health, a leading provider of high-quality behavioral health services, to expand access to mental health support for employers and their workforce nationwide. Through this strategic collaboration, Dario clients will have access to Rula's extensive network of over 15,000 providers across the country with coverage of over 120 million commercial lives through most major insurance networks. By integrating Rula's extensive reach, Dario enhances its ability to provide employers and their workforce with a more comprehensive, accessible, and effective behavioral health solution.

    DarioHealth Corp. Logo

    This strategic collaboration represents a significant step in accelerating the adoption of Dario's behavioral health solutions in the employer channel. By leveraging Rula's high-quality provider network with extensive coverage, Dario will offer an "easy button" solution for employers looking to implement behavioral health support seamlessly within their existing benefits structure.

    In addition to enhancing the accessibility of behavioral health care, the collaboration enables Dario to accelerate sales growth in the business-to-business-to-consumer ("B2B2C") channel with a comprehensive solution that Dario believes employers want. The collaboration also increases visibility in Rula's extensive partner base with organizations already seeking behavioral health support for their members and employees.

    "By combining our advanced digital health capabilities with Rula's best-in-class provider network, we can deliver a truly integrated solution that meets the needs of both employers and employees," said Steven Nelson, Chief Commercial Officer of DarioHealth. "We believe that the addition of Rula's network is the perfect complement to Dario's digital behavioral health solutions. Together, Dario and Rula enable a single, tailored journey that connects members to the right care for their needs including personalized, evidence-based behavioral health support through Dario's AI-driven engagement, digital coaching, and seamless access to licensed therapists. The collaboration further strengthens Dario's ability to provide end-to-end mental health support, reinforcing its commitment to improving health outcomes through innovative, technology-driven solutions."

    "We're excited to collaborate with DarioHealth, as this strategic arrangement directly advances our mission of making quality behavioral health care more accessible to those who need it," said Gabe Diop, Rula Co-Founder. "This collaboration allows us to continue driving innovation in whole person care—of which we know behavioral health is such a critical component—while helping individuals make meaningful progress every day that's truly personal to their unique health journey."

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

    About Rula

    Rula is the best way for individuals, couples, and families to get in-network mental health care that delivers progress. With a diverse network of more than 15,000 licensed providers, nationwide next-day therapy and psychiatric availability, and 24/7 crisis support, Rula meets people wherever they are on their mental health journey. Patients match with a best-fit provider in minutes, confirm their out-of-pocket insurance costs, attend their telehealth sessions, and track improvement all within a single easy-to-use platform. And when they need support, Rula's team is there to provide live help from real humans. Rula Health accepts most major insurance networks, including Aetna/CVS, Anthem/Elevance, Cigna/Evernorth, Kaiser, United Healthcare/Optum, and many Blue Cross and/or Blue Shield plans, covering over 120M lives. To learn more, visit https://www.rula.com.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses  the future benefits of the strategic collaboration; that the collaboration with Rula will enhance the Company's ability to provide employers and their workforce with a more comprehensive, accessible, and effective behavioral health solution that meets the needs of both employers and employees; and that the collaboration will accelerate the adoption of the Company's behavioral health solutions in the employer channel and will accelerate the Company's sales growth in the B2B2C channel. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact

    Mary Mooney

    VP Marketing

    [email protected]

    +1-312-593-4280

    DarioHealth Investor Relations Contact

    Kat Parrella

    Investor Relations Manager

    [email protected]

    +315-378-6922

    Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/dario-expands-behavioral-health-offerings-to-include-a-provider-network-through-strategic-arrangement-with-rula-302395565.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

    Findings reinforce that engagement data provide clinical signals directly impacting ROIAnalysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curveNEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform.  The observational study, titled "Machine learning and engagement insights for personalized blood glucose management," analyzed real-world data from 22,414

    3/10/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management

    As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world successGiven GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in higher ROI NEW YORK, March 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-

    3/3/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms

    Growing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and simplify digital health delivery NEW YORK, Jan. 21, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has surpassed 100 scientific studies, including peer-reviewed journal publications and peer-reviewed conference abstracts, marking a significant milestone in the Company's commitment to delivering rigorously validated outcomes for employers, health plans and their members. Reaching this thresh

    1/21/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by DarioHealth Corp.

    SCHEDULE 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/13/26 5:04:32 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    2/2/26 4:32:00 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DarioHealth Corp. (0001533998) (Filer)

    1/29/26 4:06:11 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Leisure Lawrence B. was granted 20,000 shares (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 4:20:39 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025

    Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Nov. 6, 2025 /PRNewswire/ --DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, November 13th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call. Conference Call Details Date: Thursday, November 13th, 2025, 8:30 a.m. Eastern Time Di

    11/6/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Announces 20-to-1 Reverse Stock Split

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2025, under the Company's existing trading symbol "DRIO", but will trade under a new CUSIP Number, 23725P 308. After giving effect to the reverse share split of the Company's Common Stock,

    8/25/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

    After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

    6/5/24 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care